| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
119,140,000 |
| Market
Cap: |
555.19(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.51 - $6.87 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.9 |
| Insider 3/6 Months : 22.5 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Wave Life Sciences is a genetic medicines company. Co.'s primary clinical development programs are designed to treat genetic diseases within the central nervous system, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), and muscular dystrophies, including Duchenne muscular dystrophy (DMD). These programs include: WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD; WVE-003 (silencing), its mutant huntingtin single nucleotide polymorphism 3 molecule for the treatment of HD; and WVE-N531 (splicing), its exon 53 molecule for the treatment of DMD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
5,300,000 |
5,300,000 |
14,780,052 |
| Total Buy Value |
$0 |
$26,500,000 |
$26,500,000 |
$46,882,112 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
4 |
| Total Shares Sold |
15,630 |
15,630 |
52,692 |
112,328 |
| Total Sell Value |
$96,421 |
$96,421 |
$272,540 |
$513,264 |
| Total People Sold |
1 |
1 |
1 |
4 |
| Total Sell Transactions |
1 |
1 |
2 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Moran Kyle |
Chief Financial Officer |
• – – |
2024-04-03 |
4 |
AS |
$6.17 |
$96,421 |
D/D |
(15,630) |
33,921 |
|
-22% |
|
| Shah Rajeev M. |
Director |
– • • |
2023-12-11 |
4/A |
B |
$5.00 |
$5,000,000 |
I/I |
1,000,000 |
18,202,009 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2023-12-11 |
4 |
B |
$5.00 |
$5,000,000 |
I/I |
1,000,000 |
19,202,009 |
2.25 |
22% |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2023-12-07 |
4 |
B |
$5.00 |
$16,500,000 |
I/I |
3,300,000 |
13,983,761 |
1.5 |
2% |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2023-08-23 |
4 |
AS |
$4.75 |
$176,119 |
D/D |
(37,062) |
46,120 |
|
9% |
|
| Vargeese Chandra |
See Remarks |
• – – |
2023-02-16 |
4 |
S |
$4.03 |
$41,303 |
D/D |
(10,249) |
106,624 |
|
21% |
|
| Francis Chris |
See Remarks |
• – – |
2023-02-16 |
4 |
S |
$4.03 |
$41,340 |
D/D |
(10,258) |
79,714 |
|
21% |
|
| Bolno Paul |
President and CEO |
• • – |
2023-02-16 |
4 |
S |
$4.04 |
$118,776 |
D/D |
(29,400) |
407,425 |
|
21% |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2023-02-16 |
4 |
S |
$4.04 |
$39,305 |
D/D |
(9,729) |
79,751 |
|
21% |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2023-01-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,683,761 |
|
-12% |
|
| Shah Rajeev M. |
Director |
– • • |
2022-06-16 |
4 |
B |
$2.15 |
$20,382,112 |
I/I |
9,480,052 |
17,202,009 |
2.25 |
140% |
|
| Vargeese Chandra |
Chief Technology Officer |
• – – |
2022-02-16 |
4 |
S |
$2.32 |
$24,599 |
D/D |
(10,603) |
77,809 |
|
12% |
|
| Panzara Michael A. |
See Remarks |
• – – |
2022-02-16 |
4 |
S |
$2.31 |
$24,493 |
D/D |
(10,603) |
75,817 |
|
12% |
|
| Francis Chris |
See Remarks |
• – – |
2022-02-16 |
4 |
S |
$2.31 |
$23,384 |
D/D |
(10,123) |
68,339 |
|
12% |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2022-02-16 |
4 |
S |
$2.31 |
$21,261 |
D/D |
(9,204) |
74,588 |
|
12% |
|
| Bolno Paul |
President and CEO |
• • – |
2022-02-16 |
4 |
S |
$2.32 |
$76,908 |
D/D |
(33,150) |
377,826 |
|
12% |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2021-03-24 |
4 |
OE |
$2.48 |
$27,106 |
D/D |
10,930 |
80,792 |
|
- |
|
| Panzara Michael A. |
See Remarks |
• – – |
2021-02-16 |
4 |
AS |
$10.57 |
$30,960 |
D/D |
(2,929) |
86,420 |
|
-33% |
|
| Bolno Paul |
President and CEO |
• • – |
2021-02-16 |
4 |
AS |
$10.57 |
$118,437 |
D/D |
(11,205) |
410,976 |
|
-33% |
|
| Francis Chris |
See Remarks |
• – – |
2021-02-16 |
4 |
AS |
$10.57 |
$28,518 |
D/D |
(2,698) |
78,462 |
|
-33% |
|
| Vargeese Chandra |
Chief Technology Officer |
• – – |
2021-02-16 |
4 |
AS |
$10.57 |
$33,243 |
D/D |
(3,145) |
85,412 |
|
-33% |
|
| Moran Kyle |
Chief Financial Officer |
• – – |
2021-02-16 |
4 |
AS |
$10.57 |
$18,202 |
D/D |
(1,722) |
69,862 |
|
-33% |
|
| Panzara Michael A. |
See Remarks |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
89,349 |
|
- |
|
| Bolno Paul |
President and CEO |
• • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
422,181 |
|
- |
|
| Francis Chris |
See Remarks |
• – – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
81,160 |
|
- |
|
130 Records found
|
|
Page 1 of 6 |
|
|
0.08 (1.69%) 
